Saturday Nov 30
Stocks in the News - Peregrine Pharmaceuticals (NASDAQ:PPHM), Chelsea ...
StockMarketIntel.com issues a special report on the following stocks: Peregrine Pharmaceuticals , Chelsea Therapeutics International Ltd. , On Track Innovations Ltd. , Rda Microelectronics Inc Peregrine Pharmaceuticals declined -2.14%, trading on 774,677 shares, to end the trade at $1.37.
Peregrine Pharmaceuticals Announces Upcoming Events
Piper Jaffray 25th Annual Healthcare Conference Date: Tuesday, December 3, 2013 Time: 4:00 PM Eastern Time Location: The New York Palace Hotel, New York, New York Presenter: Steven W. King, president and chief executive officer Peregrine Pharmaceuticals Second Quarter Fiscal Year 2014 Financial Results Date: Tuesday, December 10, 2013 Conference ... (more)
Investor's Watch List - Mondelez International Inc (NASDAQ:MDLZ),...
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
Stocks Alert: WebMD Health Corp. (Nasdaq:WBMD), PV Enterprises,...
WallStreetAnalyzed.com primarily focuses on NYSE, NASDAQ, and AMEX and occasionally on PINK and OTCBB companies.
News and Updates on LDHL, PPHM and MYRY
LD Holdings, Inc. is a financial and management holding company, provides various consulting services.
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List ...
Oxygen Biotherapeutics, Inc. a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up on 1,949,629 shares traded after Oxygen Biotherapeutics Received $6 Million in Net Proceeds from Warrant Exercises.
Stocks in the News- McEwen Mining Inc (NYSE:MUX), Novavax, Inc....
StockMarketIntel.com issues a special report on the following stocks: McEwen Mining Inc Novavax, Inc. ,Harmony Gold Mining Co.
Peregrine Pharmaceuticals rallies on pre-clinical data
The company says data show PS-targeting antibodies "yielded enhanced anti-tumor activity in a pre-clinical model of melanoma" when paired with an anti-CTLA-4 antibody.